BL
Therapeutic Areas
CG Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cretostimogene grenadenorepvec | BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ (CIS) | Phase 3 |
Leadership Team at CG Oncology
AK
Arthur Kuan
Chairman & Chief Executive Officer
AB
Ambaw Bellete
President & Chief Operating Officer
VK
Vijay Kasturi
Chief Medical Officer
SB
Swapnil Bhargava
Chief Technical Officer
JP
Josh Patterson
General Counsel & Chief Compliance Officer
SE
Susan E. Graf
Senior Advisor & Entrepreneur in Residence, Locust Walk (Board of Directors)
JM
Jim Mulé
Director of Cell-based Therapies, Moffitt Cancer Center (Board of Directors)
LP
Leonard Post
Chief Scientific Officer, Vivace Therapeutics (Board of Directors)
CR
Christina Rossi
Biopharmaceutical Executive & Board Member (Board of Directors)
VT
Victor Tong, Jr.
Managing Director, Decheng Capital (Board of Directors)